AstraZeneca Pharma India & Strand Life Sciences to Explore Healthcare Collaboration
The proposed collaboration aims to address barriers to timely cancer diagnosis and explore approaches to transforming cancer care for patients across India through precision diagnostics and personalised treatment.
AstraZeneca Pharma India has signed a Letter of Intent (LOI) with Strand Life Sciences, a genomics research and diagnostics company and a subsidiary of Reliance Industries, to explore potential collaboration opportunities in the Indian healthcare sector.
The proposed collaboration aims to address barriers to timely cancer diagnosis and explore approaches to transforming cancer care for patients across India through precision diagnostics and personalised treatment.
The proposed collaboration is expected to bring together AstraZeneca's pharmaceutical and oncology expertise with Strand Life Sciences' capabilities in genomics and diagnostics.
Announcing the partnership in a social post, AstraZeneca Pharma stated, “Our ambition is to eliminate cancer as a leading cause of death and bring patients closer to cure. Timely and accurate diagnosis is critical to this journey, enabling more personalised treatment approaches and better patient outcomes. Taking another step towards this vision, AstraZeneca India has signed a Letter of Intent (LOI) with Strand Life Sciences, a genomics research and diagnostics company and a subsidiary of Reliance Industries, to explore opportunities to collaborate in healthcare in India.”
Founded in 2000 and headquartered in Bengaluru, Strand Life Sciences operates in genomics, bioinformatics, precision medicine, and clinical research. Its services include next-generation sequencing (NGS)-based diagnostics, genetic testing, cancer diagnostics, biomarker discovery, and genomic data analysis.
The company also develops bioinformatics software platforms that support the analysis and interpretation of genomic data for healthcare providers, hospitals, pharmaceutical companies and medical device manufacturers.
Further, in 2021, Reliance Industries acquired a majority stake in Strand Life Sciences through its subsidiary Reliance Strategic Business Ventures as part of its broader digital healthcare initiatives.
AstraZeneca Pharma India Limited (AZPIL), headquartered in Bengaluru, Karnataka, is the Indian subsidiary of UK-based pharmaceutical company AstraZeneca. The company operates across 100 countries with focuses in areas including oncology, cardiovascular, renal and metabolism, and respiratory and immunology.
The latest development builds on AstraZeneca's continued focus on advancing oncology care in India, including the adoption of precision diagnostics and personalised cancer treatment approaches.
Months ago, AstraZeneca India signed an MoU with the Government of Andhra Pradesh to launch India's first integrated Precision Oncology ecosystem.
The facility brings together Artificial Intelligence (AI), Next Generation Sequencing (NGS), advanced genomics, and the innovation capabilities of Amaravati Quantum Valley (AQV) to advance cancer research and precision medicine, and to strengthen personalised cancer treatment.
Stay tuned for more such updates on Digital Health News